Skip to main content
David Margolis, MD, Infectious Disease, Chapel Hill, NC

DavidMMargolisMD

Infectious Disease • Chapel Hill, NC

HIV/AIDS Medicine

Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine

Join to view full profile

Dr. Margolis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Margolis' full profile

Already have an account?

  • Office

    101 Manning Dr
    Chapel Hill, NC 27599
    Phone+1 984-974-7198

Education & Training

  • University of Massachusetts Medical School
    University of Massachusetts Medical SchoolPost-Doctoral Fellowship, 1991 - 1994
  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1988 - 1991
  • Tufts Medical Center
    Tufts Medical CenterResidency, Internal Medicine, 1985 - 1988
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 1985

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2005 - 2025
  • TX State Medical License
    TX State Medical License 2001 - 2006
  • MD State Medical License
    MD State Medical License 1989 - 2001
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Fellow AAAS, 2022
  • Elected Member Association of American Physicians, 2019
  • Elected Member The American Society for Clinical Investigation, 2005
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical Studies  
    Elizabeth Connick, Michael C Sneller, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mits..., The Journal of Infectious Diseases

Press Mentions

  • Brii Biosciences Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
    Brii Biosciences Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 SubvariantsJuly 27th, 2022
  • Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
    Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 SubvariantMay 9th, 2022
  • Why COVID-19 Cases May Continue to Decline in the United States
    Why COVID-19 Cases May Continue to Decline in the United StatesApril 7th, 2022
  • Join now to see all

Dr. David Margolis, Dr. David Margolis, MD, Dr. D Margolis, Dr. David M Margolis